A few years ago a new class of cholesterol-lowering drugs were drawing a lot of praise about the potential benefits. Unfortunately, the trials since then have not delivered the same results.
Published By Ivan Oransky and Adam Marcus, STAT news, 5/19/16
In a recent article in the Bristol Herald Courier, David Balto gives a great summary of the problems with the pharmacy benefit management industry, such
In a recent article at BenefitsPRO, Dan Cook talks about the movement to have employers “rise up and fight their own battles with the drug
“Today, one in four Americans who need prescription drugs struggle to afford them — one in four,” president Joe Biden. The last two administrations have
